TMX-049 / Teijin, Xortx Therap - LARVOL DELTA

A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. (PubMed, Kidney360) - "TMX-049 200 mg reduced albuminuria at 12 weeks in patients with DKD and type 2 diabetes. TMX-049 may exert a renoprotective effect independent of its sUA-lowering effect."

Clinical • Journal • Diabetes • Diabetic Nephropathy • Gout • Immunology • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

[VIRTUAL] Effects of a Novel Xanthine Oxidase Inhibitor, TMX-049, on Urinary Albumin Excretion in Patients with Type 2 Diabetes and Albuminuria (ADA 2020) - P2 | "Once daily dosing of T40 or T200 was well tolerated in this 12-week study of participants with T2D and albuminuria. Although both doses reduced sUA, albuminuria reduction was only observed with T200. Reduced DKD progression may be achievable with TMX-049, a dual hepatic and renal XO inhibitor."

Clinical • Diabetes • Gout • Metabolic Disorders • Type 2 Diabetes Mellitus

[VIRTUAL] Effects of a Novel Xanthine Oxidase Inhibitor, TMX-049, on Urinary Albumin Excretion in Patients with Type 2 Diabetes and Albuminuria (ADA 2020) - P2 | "Once daily dosing of T40 or T200 was well tolerated in this 12-week study of participants with T2D and albuminuria. Although both doses reduced sUA, albuminuria reduction was only observed with T200. Reduced DKD progression may be achievable with TMX-049, a dual hepatic and renal XO inhibitor."

Clinical • Diabetes • Gout • Metabolic Disorders • Type 2 Diabetes Mellitus

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - P2; N=130; Completed; Sponsor: Teijin America, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - P2; N=130; Active, not recruiting; Sponsor: Teijin America, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed